Asianet Newsable on MSN
mRNA stock rallies over 40% in June: Moderna bets its future on cancer, autoimmune disease and AI-powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
Moderna Inc. MRNA announced changes to its operating model and leadership structure. The biotechnology company is preparing ...
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That ...
The company's pending vaccine approvals could help the stock continue its rise.
A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results